Latest Quarterly Report
Filed: 2026-04-30
Key Insights
- The filing indicates Clorox completed divestiture activity during the period, including the sale of the Vitamins, Minerals and Supplements business (disposed in Q3 2025), and the Glad business was still held for sale as of March 31, 2026, suggesting portfolio restructuring to focus on core operations.
- Multiple derivative instruments are in place (commodity contracts, foreign exchange forwards, interest rate contracts) indicating active hedging of commodity price volatility and foreign exchange exposure, which is critical given Clorox's exposure to raw material and international operations.
- The company maintains multiple credit facilities including revolving credit agreements and delayed draw term loans as of March 31, 2026, providing financial flexibility for operations and strategic initiatives, though specific debt levels and liquidity position require review of balance sheet details.